A Phase 3 interventional study of ALXN2060 in Symptomatic Transthyretin Amyloid Cardiomyopathy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 11 sites in Japan. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a background of stable heart failure therapy.
Participants will receive ALXN2060 for 12 months (Part A). Following the last visit (Month 12) of Part A, participants will continue the study in Part B, which will last for an additional 18 months (30 months from Day 1), during which all participants will continue to receive oral treatment with ALXN2060. Following completion of Month 30 assessments in Part B, participants will be offered the opportunity to continue to receive ALXN2060 in the Extension Period, which will last until ALXN2060 is approved in Japan or for up to 24 additional months, whichever occurs first.
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ALXN2060.
Drug: ALXN2060
ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
Also known as: AG10, Acoramidis
Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT)
The 6MWT measures how far a participant can walk in 6 minutes. Change from baseline was calculated as the difference between the distance walked during the 6MWT at 12 months and the distance walked during the 6MWT at baseline. To determine the baseline, at least 2 6MWTs were conducted \> 24 hours to ≤ 3 weeks apart prior to the first dose of ALXN2060. The baseline 6MWT is the average of the total distance walked by participants for the 2 qualifying 6MWTs that met all the protocol-defined criteria. Least squares mean change from baseline data were adjusted for baseline measures and visits.
Time frame: Baseline, Month 12
Parts A and B: Number of Cardiovascular (CV)-Related Hospitalizations Over A 30-month Period
CV-related hospitalization was defined as the mean number of CV-related hospitalizations per participant per year over a 30-month period. CV-related hospitalizations were also reported as adverse events and were reviewed and adjudicated by an independent Clinical Events Committee (CEC).
Time frame: 30 months
All-cause Mortality (ACM) Over A 30-month Period
ACM was assessed as time from the date of first initiation of study treatment to the date of death during a 30-month period, and was analyzed using Kaplan-Meier analysis. Data are reported for the number of participants with ACM over the 30-month period.
Time frame: 30 months
Parts A and B: Change From Baseline In Distance Walked During The 6MWT
The 6MWT measures how far a participant can walk in 6 minutes. Change from baseline was calculated as the difference between the distance walked during the 6MWT at specified timepoints and the distance walked during the 6MWT at baseline. To determine the baseline, at least 2 6MWTs were conducted \> 24 hours to ≤ 3 weeks apart prior to the first dose of ALXN2060. The baseline 6MWT is the average of the total distance walked by participants for the 2 qualifying 6MWTs that met all the protocol-defined criteria. Least squares mean change from baseline data were adjusted for baseline measures and visits.
Time frame: Baseline, Months 6, 9, 18, 24 and 30
Parts A and B: Change From Baseline In The Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)
The KCCQ is a 23-item questionnaire developed to measure health status and health-related quality of life in participants with heart failure. Items include heart failure symptoms, impact on physical and social functions, and how their heart failure impacts their quality of life. The overall summary score ranged from 0-100, with higher scores indicating better health status. Data presented are for change from baseline to specified timepoints. Least squares mean change from baseline data were adjusted for baseline measures and visits.
Time frame: Baseline, Months 6, 9, 12, 18, 24 and 30
Parts A and B: Number of Participants With Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
A treatment-emergent AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention that occurred after first dose. A treatment-emergent SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect that occurred after first dose. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to Month 30
Parts A and B: Change From Baseline In Serum Transthyretin (TTR) Concentration
Least squares mean change from baseline derived from with visits and baseline serum TTR as a covariate. Other covariates were included as needed.
Time frame: Baseline, pre-dose on Days 14, 28 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30
Parts A and B: Change From Baseline In TTR Stabilization
TTR stabilization was measured using fluorescent probe exclusion (FPE). Data presented are for change from baseline in FPE percentage stabilization.
Time frame: Baseline, Pre-dose Days 14, 28 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30
| Milestone | ALXN2060 |
|---|---|
| Started | 25 |
| Received at least 1 dose of study drug | 25 |
| Completed | 22 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Milestone | ALXN2060 |
|---|---|
| Started | 21 |
| Completed | 13 |
| Not completed | 8 |
| Withdrew: Adverse event | 4 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 3 |
The 6MWT measures how far a participant can walk in 6 minutes. Change from baseline was calculated as the difference between the distance walked during the 6MWT at 12 months and the distance walked during the 6MWT at baseline. To determine the baseline, at least 2 6MWTs were conducted \> 24 hours to ≤ 3 weeks apart prior to the first dose of ALXN2060. The baseline 6MWT is the average of the total distance walked by participants for the 2 qualifying 6MWTs that met all the protocol-defined criteria. Least squares mean change from baseline data were adjusted for baseline measures and visits.
| meters | ALXN2060 |
|---|---|
| Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT) | -3.86 ± 9.182 |
CV-related hospitalization was defined as the mean number of CV-related hospitalizations per participant per year over a 30-month period. CV-related hospitalizations were also reported as adverse events and were reviewed and adjudicated by an independent Clinical Events Committee (CEC).
| CV-related hospitalizations | ALXN2060 |
|---|---|
| Parts A and B: Number of Cardiovascular (CV)-Related Hospitalizations Over A 30-month Period | 0.1329 (0.0511 to 0.3457) |
The 6MWT measures how far a participant can walk in 6 minutes. Change from baseline was calculated as the difference between the distance walked during the 6MWT at specified timepoints and the distance walked during the 6MWT at baseline. To determine the baseline, at least 2 6MWTs were conducted \> 24 hours to ≤ 3 weeks apart prior to the first dose of ALXN2060. The baseline 6MWT is the average of the total distance walked by participants for the 2 qualifying 6MWTs that met all the protocol-defined criteria. Least squares mean change from baseline data were adjusted for baseline measures and visits.
| meters | ALXN2060 |
|---|---|
| Month 6 | -29.54 ± 9.316 |
| Month 9 | -23.12 ± 11.610 |
| Month 18 | -26.27 ± 12.532 |
| Month 24 | -24.89 ± 8.534 |
| Month 30 | -36.20 ± 10.798 |
The KCCQ is a 23-item questionnaire developed to measure health status and health-related quality of life in participants with heart failure. Items include heart failure symptoms, impact on physical and social functions, and how their heart failure impacts their quality of life. The overall summary score ranged from 0-100, with higher scores indicating better health status. Data presented are for change from baseline to specified timepoints. Least squares mean change from baseline data were adjusted for baseline measures and visits.
| scores on a scale | ALXN2060 |
|---|---|
| Month 6 | 0.94 ± 2.779 |
| Month 9 | -1.73 ± 3.291 |
| Month 12 | 2.71 ± 2.766 |
| Month 18 | -5.34 ± 3.747 |
| Month 24 | -0.68 ± 3.029 |
| Month 30 | -6.97 ± 3.755 |
A treatment-emergent AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention that occurred after first dose. A treatment-emergent SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect that occurred after first dose. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | ALXN2060 |
|---|---|
| Treatment-emergent AE | 25 |
| Treatment-emergent SAE | 12 |
| AEs Leading to Treatment Discontinuation | 2 |
Least squares mean change from baseline derived from with visits and baseline serum TTR as a covariate. Other covariates were included as needed.
| milligrams (mg)/deciliter (dL) | ALXN2060 |
|---|---|
| Day 14, Predose | 9.73 ± 0.886 |
| Day 28, Predose | 9.13 ± 1.256 |
| Month 3, Predose | 10.64 ± 1.056 |
| Month 6, Predose | 9.61 ± 0.847 |
| Month 9, Predose | 11.16 ± 0.744 |
| Month 12, Predose | 11.80 ± 1.157 |
| Month 15, Predose | 10.79 ± 1.347 |
| Month 18, Predose | 10.12 ± 1.253 |
| Month 21, Predose | 9.23 ± 0.704 |
| Month 24, Predose | 11.06 ± 0.848 |
| Month 27, Predose | 9.57 ± 1.020 |
| Month 30, Predose | 9.36 ± 1.280 |
TTR stabilization was measured using fluorescent probe exclusion (FPE). Data presented are for change from baseline in FPE percentage stabilization.
| percentage stabilization | ALXN2060 |
|---|---|
| Day 14, Predose | 97.15 (94.45 to 100.05) |
| Day 28, Predose | 97.29 (95.16 to 99.66) |
| Month 3, Predose | 99.09 (95.24 to 102.64) |
| Month 6, Predose | 98.56 (94.20 to 104.44) |
| Month 9, Predose | 96.47 (94.07 to 101.73) |
| Month 12, Predose | 100.89 (99.95 to 102.51) |
| Month 15, Predose | 97.65 (96.30 to 100.03) |
| Month 18, Predose | 96.75 (94.40 to 101.00) |
| Month 21, Predose | 101.30 (99.80 to 103.00) |
| Month 24, Predose | 102.60 (98.20 to 104.80) |
| Month 27, Predose | 102.65 (101.00 to 105.60) |
| Month 30, Predose | 95.60 (91.60 to 103.60) |
ACM was assessed as time from the date of first initiation of study treatment to the date of death during a 30-month period, and was analyzed using Kaplan-Meier analysis. Data are reported for the number of participants with ACM over the 30-month period.
| Participants | ALXN2060 |
|---|---|
| All-cause Mortality (ACM) Over A 30-month Period | 0 |
Collected over Up to approximately Month 57. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ALXN2060 | 1/25 (4%) | 17/25 (68%) | 25/25 (100%) |
| Event | ALXN2060 |
|---|---|
| Cardiac failure chronicCardiac disorders | 3/25 |
| Atrioventricular block completeCardiac disorders | 2/25 |
| Cardiac failureCardiac disorders | 2/25 |
| Large intestine polypGastrointestinal disorders | 2/25 |
| BradycardiaCardiac disorders | 2/25 |
| Atrial fibrillationCardiac disorders | 1/25 |
| Cardiac discomfortCardiac disorders | 1/25 |
| Sinus arrestCardiac disorders | 1/25 |
| Sinus node dysfunctionCardiac disorders | 1/25 |
| Diverticulum intestinal haemorrhagicGastrointestinal disorders | 1/25 |
| Event | ALXN2060 |
|---|---|
| ConstipationGastrointestinal disorders | 8/25 |
| NasopharyngitisInfections and infestations | 6/25 |
| Back painMusculoskeletal and connective tissue disorders | 5/25 |
| COVID-19Infections and infestations | 5/25 |
| PyrexiaGeneral disorders | 4/25 |
| HaematuriaRenal and urinary disorders | 4/25 |
| Renal impairmentRenal and urinary disorders | 4/25 |
| RashSkin and subcutaneous tissue disorders | 4/25 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 3/22 |
| AnaemiaBlood and lymphatic system disorders | 3/25 |
Full Analysis Set, which included all participants who have received at least 1 dose of ALXN2060.
| Age, Continuous(years) | ALXN2060 |
|---|---|
| Mean | 76.5 ± 6.31 |
| Sex: Female, Male(Participants) | ALXN2060 |
|---|---|
| Female | 3 |
| Male | 22 |
| Ethnicity (NIH/OMB)(Participants) | ALXN2060 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 25 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | ALXN2060 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 25 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Nov 2023, 35 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acoramidis
Alexion Pharmaceuticals, Inc. →